Spanish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Dexamethasone and Induction of Delivery

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
El enlace se guarda en el portapapeles.
EstadoTerminado
Patrocinadores
samar sayed el sayed

Palabras clave

Abstracto

This study aims to evaluate the effect of intravenous injection of a single dose of dexamethasone in shortening the duration interval between initiation of labor induction and delivery of the fetus in primigravida full-term pregnancy.

Descripción

Research hypothesis:

In full term primigravidae undergoing induction of labor, the use of a single dose of dexamethasone (8mg) intra-venously will help in shortening the duration interval between initiation of labor induction and delivery of the fetus.

Research question:

In full term primigravidae undergoing induction of labor, does the use of intra-venous dexamethasone play a role in shortening the duration interval between initiation of labor induction and delivery of the fetus?

Patients and Methods

Type of study:

Double blind randomized controlled trial.

Study settings:

Site: Ain Shams Maternity Hospital Study duration: 6 months

Study population:

One hundred and two pregnant women will be recruited in this study from women attending the emergency room department of obstetrics and gynecology at Ain Shams University.

Inclusion criteria:

Primiparity Singleton pregnancy Gestational age i.e. 40 weeks or more by date or 1st trimestric ultrasound. Bishop score of 4 or greater. Longitudinal lie. Vertex presentation. Intact membranes

Exclusion criteria:

Refused consent Malpresentation. Multiple pregnancies. Active phase of labour. Rupture of membranes (ROM). Cephalo-pelvic disproportion. Previous C-section or myomectomy operation. Known contraindication or hypersensitivity to Dexamethasone. Fetal distress. IUFD Current maternal disorder e.g. diabetes mellitus and pregnancy induced hypertension.

Over distended abdomen e.g. fetal macrosomia or polyhydramonus suggested by ultrasound.

Ante-partum hemorrhage e.g. placenta previa, accidental hemorrhage.

These criteria will be assessed at first during the initial evaluation in the delivery suite as follows:

History:

Personal, menstrual, obstetric, past and family history will be taken. History of present pregnancy will be taken including the first day of last menstrual period, duration of pregnancy, warning symptoms as headache, visual symptoms, edema of face and fingers, excessive vomiting, heart burn, epigastric pain, vaginal bleeding, decreased fetal movements, edema of the lower limbs and history of any drug intake.

Examination:

1. General examination:vital signs, chest, heart and lower limb examination.

2. Abdominal examination: for assessment of fundal level, presentation, expected fetal weight, fetal heart rate and presence of scars of previous operations as cesarean section or myomectomy.

3. Vaginal examination: for assessment of cervical dilatation and effacement at the beginning, state of fetal membranes, station of fetal head, position of fetal head and pelvic adequacy.

Investigations:

1. Laboratory: blood grouping, Rh typing, complete blood count.

2. Abdominal ultrasound: to confirm the gestational age, fetal number, viability, presentation, position, estimated fetal weight, and to detect the grade of placental maturity, amount and turbidity of liquor.

3. CTG: application of CTG half an hour to all participates before starting any intervention.

Enrollment and Allocation of the patients:

After approval of health ethical committee in Ain Shams Hospital and after the initial evaluation, women who fulfilled the appropriate inclusion and exclusion criteria will be invited to participate in the study, a verbal consent will be obtained from each candidate after explanation of the procedure in details.

Randomization:

The eligible 102 women will be randomized into one of the following two groups:

1. Group D (study group): including 51 women who will receive a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously.

2. Group P (control group): including 51 women who will receive a prefilled syringe with two milliliters of distilled water intravenously.

No cervical ripping agent will be used for induction of labor in either group. Randomization is performed using a computer-generated randomization system. 102 opaque envelopes will be numbered serially; each envelope will contain the corresponding letter in the randomization table, and when the first pregnant woman arrived, the first envelope will be opened and the pregnant woman will be allocated to the group according to the inside letter.

fechas

Verificado por última vez: 08/31/2018
Primero enviado: 08/28/2018
Inscripción estimada enviada: 09/01/2018
Publicado por primera vez: 09/04/2018
Última actualización enviada: 09/01/2018
Última actualización publicada: 09/04/2018
Fecha de inicio real del estudio: 12/31/2017
Fecha estimada de finalización primaria: 04/14/2018
Fecha estimada de finalización del estudio: 06/29/2018

Condición o enfermedad

Induction of Labor Affected Fetus / Newborn

Intervención / tratamiento

Drug: Group D

Drug: Group P

Fase

Fase 1

Grupos de brazos

BrazoIntervención / tratamiento
Active Comparator: Group D
including 51 women who will receive a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously.
Drug: Group D
a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously
Placebo Comparator: Group P
including 51 women who will receive a prefilled syringe with two milliliters of distilled water intravenously.
Drug: Group P
a prefilled syringe with two milliliters of distilled water intravenously.

Criterio de elegibilidad

Sexos elegibles para estudiarFemale
Acepta voluntarios saludablessi
Criterios

Inclusion Criteria:

- Primiparity

- Singleton pregnancy

- Gestational age i.e. 40 weeks or more by date or 1sttrimestric ultrasound.

- Bishop score of 4 or greater.

- Longitudinal lie.

- Vertex presentation.

- Intact membranes

Exclusion Criteria:

- Refused consent

- Malpresentation.

- Multiple pregnancies.

- Active phase of labour.

- Rupture of membranes (ROM).

- Cephalo-pelvic disproportion.

- Previous C-section or myomectomy operation.

- Known contraindication or hypersensitivity to Dexamethasone.

- Fetal distress.

- IUFD

- Current maternal disorder e.g. diabetes mellitus and pregnancy induced hypertension.

- Over distended abdomen e.g. fetal macrosomia or polyhydramonus suggested by ultrasound.

- Ante-partum hemorrhage e.g. placenta previa, accidental hemorrhage.

Salir

Medidas de resultado primarias

1. The interval between the initiation of induction and the delivery of the fetus. [Up to 1 day]

Mean time of interval between the initiation of induction and the delivery of the fetus in the two groups.

Medidas de resultado secundarias

1. The duration of the first stage of labor (Partographic representation will do for each participant). [Up to 1 hour]

Mean time of duration of the first stage of labor in the two groups.

2. The duration of the second stage of labor. [Up to 2 hours]

Mean time of duration of the second stage of labor in the two groups.

3. The duration of the third stage of labor. [Up to 30 minutes]

Mean time of duration of the third stage of labor in the two groups.

4. The neonatal outcome by APGAR score. [at 1 and 5 minutes]

Mean of APGAR score at 1 and 5 minutes for fetus in the two groups.

5. Any postpartum maternal adverse effects (e.g. vital sing abnormality, any maternal postpartum hemorrhage and central nervous system manifestation). [Up to 1 day]

Percentage of postpartum adverse effects in both group.

Únete a nuestra
página de facebook

La base de datos de hierbas medicinales más completa respaldada por la ciencia

  • Funciona en 55 idiomas
  • Curas a base de hierbas respaldadas por la ciencia
  • Reconocimiento de hierbas por imagen
  • Mapa GPS interactivo: etiquete hierbas en la ubicación (próximamente)
  • Leer publicaciones científicas relacionadas con su búsqueda
  • Buscar hierbas medicinales por sus efectos.
  • Organice sus intereses y manténgase al día con las noticias de investigación, ensayos clínicos y patentes.

Escriba un síntoma o una enfermedad y lea acerca de las hierbas que podrían ayudar, escriba una hierba y vea las enfermedades y los síntomas contra los que se usa.
* Toda la información se basa en investigaciones científicas publicadas.

Google Play badgeApp Store badge